Alluvi Tirzepatide 

Tirzepatide BNF: UK Prescribing and Safety Information

Searching for tirzepatide BNF information usually means looking for reliable UK guidance covering the medicine’s indications, dosage forms, cautions, interactions and possible side effects.

At
Alluvi Healthcare,
visitors can review a factual tirzepatide overview, compare related catalogue information and understand why Mounjaro requires a prescription and an appropriate clinical assessment.

Tirzepatide is a long-acting medicine that activates both glucose-dependent insulinotropic polypeptide receptors, known as GIP receptors, and glucagon-like peptide-1 receptors, known as GLP-1 receptors.

In the UK, authorised tirzepatide is supplied under the Mounjaro brand as a solution for injection in a multidose pre-filled KwikPen.

This page is not produced by, affiliated with or endorsed by the British National Formulary or NICE. It provides a plain-language summary and links directly to official sources.

Consult the Official Tirzepatide BNF Entry

Healthcare professionals and visitors seeking the current formulary entry should consult the

official NICE British National Formulary entry for tirzepatide
.

The BNF provides professional medicine information concerning:

• Licensed indications
• Dosage and administration
• Cautions and contraindications
• Medicine interactions
• Common and serious adverse effects
• Pregnancy and breastfeeding considerations
• Renal and hepatic impairment
• Patient and carer advice
• Medicinal forms and NHS pricing information

BNF content can change when product licences, safety warnings or clinical guidance are updated. Always use the live official entry rather than relying on screenshots, copied dosage charts or old social-media posts.

Review the Alluvi Tirzepatide Information Page

Visitors can review the

Alluvi Tirzepatide product-information page

for the current catalogue title, images, stated presentation and related store information.

Before proceeding with any medicine-related service, confirm:

• Whether a regulated clinical consultation is provided
• The identity and registration of the dispensing pharmacy
• That a prescription is required before supply
• The exact licensed brand being considered
• The prescribed strength and presentation
• The pack size and number of doses
• The current patient-information leaflet
• The applicable delivery and storage arrangements
• The process for reporting side effects or defective products

Tirzepatide must not be supplied as an unrestricted retail product or selected solely by choosing a preferred strength from an online product menu.

What Is the British National Formulary?

The British National Formulary, commonly abbreviated to BNF, provides UK healthcare professionals with practical information supporting the selection, prescribing, dispensing and administration of medicines.

A BNF monograph is not the same as an online product description. It is designed to support professional decision-making and should be considered alongside:

• The individual patient’s medical history
• The licensed product information
• Current NICE guidance
• Local formulary and NHS commissioning rules
• Relevant laboratory and clinical monitoring
• The prescriber’s professional judgement

Searchers should not use the phrase “BNF” as proof that a website, seller or product is officially connected with NICE.

What Is Tirzepatide?

Tirzepatide is a synthetic peptide-based medicine engineered to activate the GIP and GLP-1 receptor systems.

These receptors are involved in processes including:

• Glucose-dependent insulin secretion
• Glucagon regulation
• Appetite and food-intake signalling
• Gastric emptying
• Blood-glucose control
• Body-weight regulation

Tirzepatide delays gastric emptying, with the effect generally becoming less pronounced over time. Its glucose-lowering activity can increase the risk of hypoglycaemia when it is used alongside insulin or certain other diabetes medicines.

Licensed UK Uses of Mounjaro

The current UK

Mounjaro Summary of Product Characteristics

should be consulted for the complete licensed indications.

Type 2 diabetes

Mounjaro is authorised as an adjunct to diet and exercise for insufficiently controlled type 2 diabetes.

The licence covers adults and, for type 2 diabetes, children and adolescents aged 10 years and over. It may be used alone when metformin is inappropriate or alongside other diabetes medicines when clinically suitable.

Adult weight management

Mounjaro is also authorised for adult weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity.

The licensed criteria include adults with:

• A body mass index of at least 30 kg/m²; or
• A body mass index from 27 kg/m² to below 30 kg/m² with at least one weight-related health condition.

Licensed eligibility is not the same as NHS-funded eligibility. NHS access may be narrower and introduced according to phased commissioning arrangements.

Tirzepatide BNF Dosage Overview

Tirzepatide dosing must be determined and reviewed by an authorised prescriber. Do not use this page to start treatment, select a strength or change an existing prescription.

The UK product information describes a once-weekly starting regimen with gradual dose escalation. In adults, licensed maintenance strengths include 5mg, 10mg and 15mg, with intermediate strengths used during escalation where appropriate.

Dose escalation is gradual because gastrointestinal adverse effects are more likely during the early stages of treatment and after an increase.

The prescribed dose may be influenced by:

• The authorised indication
• Treatment response
• Adverse effects and tolerability
• Concurrent diabetes medicines
• Risk of low blood glucose
• Pregnancy plans
• Medical history and current conditions

Never extract additional liquid from a used KwikPen or calculate an unofficial “extra dose.” Follow the current patient leaflet and instructions supplied with the prescribed pen.

Available Mounjaro KwikPen Strengths

UK Mounjaro KwikPens are available in several strengths:

• 2.5mg per dose
• 5mg per dose
• 7.5mg per dose
• 10mg per dose
• 12.5mg per dose
• 15mg per dose

Each multidose KwikPen is designed to provide four labelled doses. A higher-strength pen is not automatically more appropriate, more effective or more economical for an individual patient.

Only use the exact strength stated on the prescription and dispensing label.

BNF, SmPC and NICE Guidance Are Not the Same

These official resources serve related but different purposes.

• The BNF provides practical UK prescribing, dispensing, interaction and safety information.
• The Summary of Product Characteristics contains the regulator-approved professional information for the licensed medicine.
• NICE technology-appraisal guidance evaluates clinical and cost effectiveness and makes recommendations for NHS use.

NICE recommends tirzepatide as an NHS option for managing overweight and obesity in specified adults, alongside dietary and physical-activity support.

Review the

NICE tirzepatide weight-management guidance

for the current recommendations and implementation information.

NHS England is introducing access in phases. Meeting the medicine’s licensed criteria does not automatically mean immediate NHS eligibility.

Common Tirzepatide Side Effects

The most frequently reported effects are gastrointestinal. They are often most noticeable during initial treatment and dose escalation.

Reported effects include:

• Nausea
• Diarrhoea
• Vomiting
• Constipation
• Abdominal pain
• Indigestion
• Reduced appetite
• Abdominal bloating
• Injection-site reactions

Vomiting and diarrhoea can cause dehydration. People who cannot keep fluids down, become unusually weak or develop signs of significant dehydration should seek appropriate medical advice.

Acute Pancreatitis Warning

Acute pancreatitis has been reported with tirzepatide and other medicines acting through GLP-1 pathways.

In January 2026, the MHRA strengthened product warnings following rare reports that included necrotising and fatal pancreatitis.

Review the

official MHRA pancreatitis safety update
.

Severe, persistent abdominal pain—particularly pain that travels to the back and may occur with nausea or vomiting—requires urgent medical assessment.

Treatment should not be restarted after pancreatitis has been confirmed unless an appropriate healthcare professional has reviewed the situation in accordance with current guidance.

Tirzepatide Interactions and Clinical Checks

The full interaction list should be checked through the

official BNF tirzepatide interactions page
.

Particularly important considerations include:

• Insulin and sulfonylureas, which can increase hypoglycaemia risk
• Medicines requiring careful absorption or precise blood concentrations
• Oral medicines potentially affected by delayed gastric emptying
• Other weight-management or incretin-based medicines
• Changes to diabetes treatment made during rapid weight loss

Do not combine tirzepatide with another GLP-1 or weight-management medicine unless an authorised prescriber has assessed and directed the combination.

Oral Contraception and Tirzepatide

Tirzepatide’s effect on gastric emptying may reduce the reliability of oral contraception in people who are overweight or have obesity during specific treatment periods.

Current MHRA guidance advises adding a barrier method or changing to a non-oral contraceptive method for four weeks after starting Mounjaro and for four weeks following each dose increase.

Discuss contraception with the prescriber or another suitably qualified healthcare professional rather than relying solely on general website information.

Pregnancy and Breastfeeding

Tirzepatide should not be used during pregnancy. Anyone who becomes pregnant or believes they may be pregnant should contact a healthcare professional promptly.

Current MHRA public guidance advises stopping tirzepatide at least one month before a planned pregnancy.

The MHRA’s public advice states that GLP-1 medicines should not be used while breastfeeding because safety information remains insufficient.

Review the

MHRA guidance for people using GLP-1 medicines

and discuss individual circumstances with a qualified professional.

Surgery, Sedation and Delayed Gastric Emptying

People taking tirzepatide should inform their surgical and anaesthetic team before an operation or procedure involving general anaesthesia or deep sedation.

Tirzepatide can delay stomach emptying, which may increase the risk of residual stomach contents entering the airway during a procedure.

Do not stop a prescribed medicine independently before surgery. The healthcare team should provide individual instructions.

Buying Genuine Tirzepatide Safely

Tirzepatide is a prescription-only medicine. A legitimate private supply requires a consultation with an authorised healthcare professional before a prescription is issued.

The MHRA advises obtaining GLP-1 medicines only through a legitimate registered pharmacy. Powder supplied in a vial for mixing is not an authorised UK presentation of Mounjaro.

Warning signs include:

• No clinical consultation
• No prescription requirement
• Unlabelled powder or multidose vials
• Claims of unrestricted supply
• Social-media or messaging-app sales
• Guaranteed weight-loss claims
• No registered pharmacy details
• Unusually altered or defective pen components

A February 2026 MHRA alert identified falsified Mounjaro 15mg pens carrying a specific batch number. This demonstrates that professional-looking packaging alone cannot prove authenticity.

Review the

MHRA falsified Mounjaro KwikPen alert

for the official affected-product information.

Compare Related Alluvi Information

Visitors can review the following catalogue pages for factual comparison:

• 
  Tirzepatide information
  
• 
  Alluvi Tirzepatide information
  
• 
  Mounjaro information
  
• 
  Semaglutide information
  
• 
  Wegovy information
  

These products and listings may have different active ingredients, licensed uses, presentations and prescription requirements. Internal links are provided for information and navigation rather than personalised treatment recommendations.

Frequently Asked Questions About Tirzepatide BNF

Is tirzepatide listed in the BNF?

Yes. The BNF has a tirzepatide monograph covering indications, dose information, cautions, interactions, side effects and medicinal forms.

What is the UK brand name for tirzepatide?

Authorised tirzepatide is marketed in the UK under the Mounjaro brand.

Is tirzepatide prescription only?

Yes. It requires a prescription issued following an appropriate assessment by an authorised healthcare professional.

Is tirzepatide licensed for weight management?

Mounjaro is licensed for adult weight management in people meeting the criteria described in its UK product information.

Is BNF eligibility the same as NHS eligibility?

No. The product licence and BNF describe medical use, while NICE and NHS commissioning arrangements determine funded access.

What are the most common tirzepatide side effects?

Commonly reported effects include nausea, diarrhoea, vomiting, constipation, abdominal discomfort and reduced appetite.

What symptom may indicate pancreatitis?

Severe, persistent abdominal pain that may travel to the back—sometimes with nausea or vomiting—requires urgent medical attention.

Can tirzepatide affect the contraceptive pill?

It may reduce oral contraceptive reliability in people who are overweight or have obesity after starting treatment and after dose increases. Follow current MHRA and prescriber guidance.

Can tirzepatide be used during pregnancy?

No. It should not be used during pregnancy and should be stopped in advance of a planned pregnancy according to current professional guidance.

Can I buy tirzepatide without a consultation?

No legitimate UK supply should bypass the required clinical consultation and prescription process.

Where can I read the official monograph?

Consult the

official tirzepatide BNF page
.

Use Tirzepatide BNF Information Responsibly

Tirzepatide BNF searches should lead visitors toward reliable prescribing, interaction and safety information—not toward unsupervised treatment or unrestricted medicine sales.

Consult the official BNF, current Mounjaro product literature and NICE guidance, and complete an appropriate clinical assessment before treatment is considered.

Review the

Alluvi Tirzepatide information page

for related catalogue information without treating the page as a prescription or replacement for professional advice.

Check the BNF. Confirm the licensed product. Use tirzepatide only through a regulated prescription pathway.